Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848206 · ClinicalTrials.gov registry record
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 251,831
- Enrollment target
NCT05848206: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05848206 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 251,831 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05848206 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 251,831 participants
- Enrollment target
Study Summary
This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251,831 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2022-04-29 |
What the finished NCT05848206 record still lists
NCT05848206 is an observational study that tracks outcomes without assigning an intervention. Its 251,831 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05848206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05848206 about?
NCT05848206 is a clinical study titled "Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.". This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
What is the current status of trial NCT05848206?
This trial is currently completed. The enrollment target is 251,831 participants. The study started on 2022-03-11. Estimated completion is 2022-04-29.
Who is sponsoring clinical trial NCT05848206?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI